Resiliva Tablet contains Resmetirom, a selective thyroid hormone receptor-beta (THR-β) agonist, indicated for the treatment of adults with noncirrhotic nonalcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosis (F2–F3 stages). When used in conjunction with diet and exercise, Resiliva helps reduce intrahepatic triglycerides and improves liver function by selectively activating THR-β in the liver while minimizing systemic thyroid effects.

Resmetirom has demonstrated high specificity for THR-β, producing 83.8% of the maximum response compared to triiodothyronine (T3), and a much lower effect on THR-α, reducing potential cardiovascular side effects. Activation of THR-β in the liver supports reduction of liver fat and contributes to the management of NASH.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Indications

Resiliva is indicated for:

• Adults with noncirrhotic NASH

• Moderate to advanced liver fibrosis (F2–F3)

• As part of lifestyle intervention including diet and exercise

Pharmacology

• Mechanism of Action: Selective activation of thyroid hormone receptor-beta (THR-β) in the liver

• Effects: Reduces intrahepatic triglycerides, improves liver metabolism, and supports fibrosis reduction

• Selectivity: Minimal activity on THR-α, reducing potential cardiovascular effects

Dosage & Administration

• Dose: Based on actual body weight

• Administration: Can be taken with or without food

• Follow physician guidance on dose adjustments based on patient response

Drug Interactions

• CYP2C8 inhibitors: Strong inhibitors (e.g., Gemfibrozil) are not recommended; moderate inhibitors (e.g., Clopidogrel) may require dose reduction

• OATP1B1 and OATP1B3 inhibitors: Avoid co-administration (e.g., Cyclosporine)

• Statins: Resiliva increases plasma concentrations of Atorvastatin, Pravastatin, Rosuvastatin, and Simvastatin; dose adjustment recommended

• CYP2C8 substrates: Monitor closely if co-administered (e.g., Pioglitazone)

Side Effects

Common side effects include:

• Diarrhea

• Nausea and vomiting

• Abdominal pain

• Dizziness

• Pruritus

• Constipation

Precautions & Warnings

• Hepatotoxicity: Monitor liver function tests; discontinue if significant liver injury occurs

• Gallbladder events: Cholelithiasis, acute cholecystitis, and obstructive pancreatitis observed; interrupt treatment if suspected

• Drug interactions with statins: Adjust statin dosage to avoid adverse reactions

• Special populations: Use caution in elderly patients, patients with moderate/severe hepatic impairment, and avoid in decompensated cirrhosis

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Pregnancy & Lactation

• No human data available; use only if clearly needed during pregnancy

• Effects on breastfeeding are unknown; discontinue nursing during treatment

Use in Special Populations

• Pediatrics: Safety and efficacy not established

• Elderly: Slightly higher incidence of adverse reactions

• Renal impairment: No dose adjustment for mild/moderate impairment; severe impairment not studied

• Hepatic impairment: Avoid in moderate to severe impairment (Child-Pugh B or C); no adjustment needed for mild impairment

Storage Conditions

• Store below 30°C in a cool, dry place, away from light

• Keep out of reach of children.